Vismodegib Brand Name – Erivedge
What is Vismodegib
Vismodegib is an oral hedgehog pathway inhibitor. It is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC) or in patients with locally advanced BCC that has recurred following surgery.
Vismodegib is also indicated for patients with locally advanced BCC who are not candidates for surgery or radiation therapy.
Vismodegib may cause embryo-fetal death or severe birth defects when administered during pregnancy.
Indications
- basal cell carcinoma
For the treatment of basal cell carcinoma (BCC)
for the treatment of metastatic BCC or locally advanced BCC that has recurred following surgery or in patients who are not candidates for surgery or radiation
Side Effects
- alopecia
- amenorrhea
- anorexia
- anorexia
- arthralgia
- arthralgia
- azotemia
- constipation
- diarrhea
- diarrhea
- dysgeusia
- fatigue
- fatigue
- fetal death
- growth inhibition
- hepatotoxicity
- hypokalemia
- hyponatremia
- muscle cramps
- muscle cramps
- nausea
- nausea
- new primary malignancy
- teratogenesis
- vomiting
- weight loss
- weight loss
Monitoring Parameters
- pregnancy testing
Contraindications
- blood donation
- breast-feeding
- children
- contraception requirements
- growth inhibition
- infants
- infertility
- intrauterine fetal death
- male-mediated teratogenicity
- neonates
- precocious puberty
- pregnancy
- pregnancy testing
- reproductive risk
Interactions
- Clozapine
- grapefruit juice
- Warfarin
